Lymphoma Trial, Recruiting NCT05700149 Sponsor: International Extranodal Lymphoma Study Group (IELSG) Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT05700149
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who have been diagnosed with a specific type of lymphoma called Nodal Marginal Zone Lymphoma (NMZL), confirmed by a lymph node tissue sample taken after January 1st, 2000
  • People for whom a stored tumour tissue sample from a lymph node is available — either frozen or preserved in a special wax (FFPE) — that was collected before any treatment was given
  • People for whom baseline (starting point) and follow-up medical records and information are available

Who may not be able to join:

  • People whose lymphoma in the lymph nodes has been found to have spread from a hidden primary lymphoma that started outside the lymph nodes (the trial requires that this possibility has been carefully ruled out using imaging or a camera examination of the relevant areas)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Davide Rossi, MD, Oncology Institute of Southern Switzerland and Institute of Oncology Research

Phone: +41586667321

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Registry
ClinicalTrials.gov
Start date
11 April 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇦🇷 Argentina Armenia 🇨🇦 Canada 🇭🇷 Croatia 🇫🇷 France 🇮🇳 India 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal 🇰🇷 South Korea 🇪🇸 Spain 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Define and quantify molecular subsets.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov